Industry News
Biotechnology Industry News
Lynk Pharmaceuticals has reported…
Lynk Pharmaceuticals has reported another phase 3 win in China for its next-gen JAK inhibitor, this time hitting skin clearance goals among patients with eczema.
A second phase 3 study of…
A second phase 3 study of Roche’s fenebrutinib in relapsing multiple sclerosis has hit its primary endpoint, positioning the company to submit the BTK inhibitor for approval. But the discovery that more patients died on
Aardvark Therapeutics has seen its…
Aardvark Therapeutics has seen its share price halve in value after the company paused a phase 3 study of its lead metabolic asset over heart-related data.
BioNTech and partner DualityBio…
BioNTech and partner DualityBio are accelerating the development of their B7-H3 ADC into a phase 3 trial for metastatic castration-resistant prostate cancer (mCRPC). With encouraging phase 1/2 data, the partners are aiming to achieve success
On some level, Eli Lilly’s…
On some level, Eli Lilly’s partnership with computing giant Nvidia feels inevitable. The first pharma to reach a $1 trillion valuation teaming up with a tech firm that has ridden the AI wave to a
A new biotech has risen from the…
A new biotech has risen from the ashes of Novartis’ red-hot $12 billion acquisition of muscular dystrophy specialist Avidity Biosciences. A spinout planned since that deal’s October announcement has now officially debuted as Atrium Therapeutics,
AI research biotech Earendil Labs…
AI research biotech Earendil Labs has penned an $885 million deal to use WuXi XDC’s linker-payload technology to create next-gen antibody-drug conjugates.
Generate:Biomedicines is the…
Generate:Biomedicines is the latest biotech to benefit from a renewed appetite from investors for publicly listed drug developers.
A “fairly shocking and certainly…
A “fairly shocking and certainly ironic twist of fate” is ending Sarepta Therapeutics’ CEO Doug Ingram’s nearly decade-long tenure at the helm of the gene therapy maker, he said on an investor call. The executive
A panel of physicians, biotech…
A panel of physicians, biotech leaders and patient advocates took aim at the FDA during a Senate hearing on how the agency’s bureaucracy affects innovation.
From AI to wearables, physiology…
From AI to wearables, physiology turns data into discovery and drives smarter drug development.
The trial was the first to assess…
The trial was the first to assess R-MDMA in patients with social anxiety disorder, AtaiBeckley CEO Srinivas Rao said in a statement.
A Chinese phase 3 trial of Bristol…
A Chinese phase 3 trial of Bristol Myers Squibb’s antibody-drug conjugate has hit its dual primary survival endpoints, providing further validation of the Big Pharma's $800 million bet on the candidate.
While the FDA mulls whether to…
While the FDA mulls whether to approve Protagonist Therapeutics’ hematology asset, the biopharma is thinking it will pocket $400 million rather than split profits with Takeda.
Accent Therapeutics has halted…
Accent Therapeutics has halted work on a solid tumor drug due to adverse events in a phase 1/2 study.
Japanese conglomerate Asahi Kasei…
Japanese conglomerate Asahi Kasei is acquiring Aicuris in a $920 million deal that will allow Asahi to add approved and investigational assets designed to treat and protect against viral infections in immunocompromised individuals.
The federal government is pledging…
The federal government is pledging as much as $144 million to anti-aging research over the next five years through the Advanced Research Projects Agency for Health (ARPA-H), a subject area previously named as a priority
Boehringer is banking on the…
Boehringer is banking on the program offering a new oral and precision approach to modulating disease-driving immune cells.
After dumping its sole remaining…
After dumping its sole remaining gene therapy asset last year, Pfizer has decided to exercise its option for global rights to Beam Therapeutics’ liver-targeted gene editing candidate.
Like Merck & Co.’s PAH drug…
Like Merck & Co.’s PAH drug Winrevair—which brought in $1.4 billion last year—35Pharma's HS235 targets the activin receptor signaling pathway.